ARS Pharmaceuticals, Inc. (SPRY) Operating margin 2021–2025
ARS Pharmaceuticals, Inc. (SPRY) operating margin by fiscal year — reported operating income divided by reported revenue.
-212.9%FY2025 · since FY2021: -353.3% → -212.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -212.9% | -209.5 pp |
| FY2024 | -3.5% | +225063.2 pp |
| FY2023 | -225066.7% | -222367.9 pp |
| FY2022 | -2698.8% | -2345.5 pp |
| FY2021 | -353.3% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRY financial trends
SPRY RevenueSPRY Net incomeSPRY Net marginSPRY Gross profitSPRY Gross marginSPRY Operating incomeSPRY Operating cash flowSPRY Free cash flowSPRY Capital expendituresSPRY Return on equitySPRY Stock buybacksSPRY Dividends paidSPRY Total assetsSPRY Total liabilitiesSPRY Shareholders’ equitySPRY overview →